NYEE HomeThe New York Eye and Ear Infirmary
Patient InfoHealthcare ProfessionalsSpecialties & ServicesSupport NYEEAbout Us
  Current Research
Clinical Trials in Ophthalmology
Ophthalmology
Research

Otolaryngology
Research

Pathology
& Laboratory Medicine
Research

Plastic &
Reconstructive
Surgery
Research

Institutional
Review Board
(IRB)

 
printer-friendly version of this pagePrinter-Friendly Page large print version of this pageLarge Print Version 

An 8-Week, Multicenter, Masked, Randomized Trial (with an 18-Week Masked Extension) to Assess the Safety and Efficacy of 700 μg and 350 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System Compared with Sham DEX PS DDS Applicator System in the Treatment of Non-Infectious Ocular Inflammation of the Posterior Segment in Patients with Intermediate Uveitis

Principal Investigator: C. Michael Samson, MD

Enrollment Status: Open  

Objective:  To evaluate the safety and efficacy of the 700 μg DEX PS DDS Applicator System (700 μg dexamethasone) compared with the 350 μg DEX PS DDS Applicator System (350 μg dexamethasone) in the treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate uveitis. (700 μg dexamethasone vs. 350 μg dexamethasone)

Eligibility:  Contact Principal Investigator/Coordinator. 

Contact Information:  

  • Principal Investigator: C. Michael Samson, MD at (212) 979-4919
  • Study Coordinators: Julie Paa, (212) 979-4024 and Katy Tai, CR Manager (212) 979-4251

 

Home > Current Research > Clinical Trials in Ophthalmology > An 8-Week, Multicenter, Masked, Randomized Trial (with an 18-Week Masked Extension) to Assess the Safety and Efficacy of 700 μg and 350 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System Compared with Sham DEX PS DDS Applicator System in the Treatment of Non-Infectious Ocular Inflammation of the Posterior Segment in Patients with Intermediate Uveitis